Skip to content
HowShorted

Apellis Pharmaceuticals, Inc. short interest in 2025

In 2025, Apellis Pharmaceuticals, Inc.'s disclosed short interest ran from 14.50% of shares outstanding on 15 Jan 2025 to 12.74% on 31 Dec 2025, a change of -1.76 percentage points. The year's high was 22.89% on 30 Apr 2025 and its low 12.02% on 31 Oct 2025, averaging 16.44% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.00 days on 30 Jun 2025. Full history: Apellis Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Apellis Pharmaceuticals, Inc. in 2025

2025 in figures

Start of year
14.50% (15 Jan 2025)
End of year
12.74% (31 Dec 2025)
Change
-1.76 pp
High
22.89% (30 Apr 2025)
Low
12.02% (31 Oct 2025)
Average
16.44%
Highest days to cover
14.00 (30 Jun 2025)
SEC filings marked
5

Every report in 2025

Apellis Pharmaceuticals, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202514.50%7.15results (8-K)
31 Jan 202513.71%11.57
14 Feb 202513.94%12.04
28 Feb 202516.73%11.9810-K filed
14 Mar 202515.53%13.18
31 Mar 202518.10%10.40
15 Apr 202521.57%8.71
30 Apr 202522.89%12.71
15 May 202521.68%8.1110-Q filed
30 May 202519.92%9.96
13 Jun 202520.00%11.08
30 Jun 202520.81%14.00
15 Jul 202513.12%8.47
31 Jul 202517.49%7.2610-Q filed
15 Aug 202516.05%6.96
29 Aug 202516.26%11.61
15 Sep 202517.23%9.67
30 Sep 202516.67%9.31
15 Oct 202514.30%8.09
31 Oct 202512.02%4.4310-Q filed
14 Nov 202512.92%5.59
28 Nov 202512.72%7.55
15 Dec 202513.63%7.71
31 Dec 202512.74%7.29

See also: Apellis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.